Augmentation of antidepressant pharmacotherapy: A preclinical approach using the mouse forced swimming test

CNS Spectrums

Volumn 4, Issue 4, 1999, Pages 73-81

  Redrobe, John P ^a   Bourin, Michel ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; CLONIDINE; FLUOXETINE; FLUVOXAMINE; GLIBENCLAMIDE; IMIPRAMINE; MIANSERIN; ONDANSETRON; PAROXETINE; PINDOLOL; QUININE; RITANSERIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; DEPRESSION; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; FORCED SWIMMING TEST; LOCOMOTION; MOOD; MOUSE; NONHUMAN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM;

EID: 0032953867     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900011573     Document Type: Review

References (47)

1. Porsolt RD, Bertin A, Jalfre M. Behavioural despair in mice: a primary screening test for antidepressanls. Arch Int Pharmacodyn Ther. 1977;229:327-336.
2. Borsini F, Meli A. Is the forced swimming test a suitahle model for revealing antidepressant activity? Psychopharmacology. 1988;94:147-160.
3. Borsini F. Role of the serotonergic system in the forced swimming test. Neurosci Biobehav Rei: 1995;19: 377-395.
4. Porsolt RD, Anton G, Blavet N, Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol. 1978;47:379-391.
5. Porsolt RD, Bertin A, Blavet N, Deniel M, Jalfre M. Immohility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity. Eur J Pharmacol. 1979;57:201-210.
6. Detke MJ, Wieland S, Lucki I. Blockade of the antidepressant-like effects of 8-OH-DPAT, buspirone and desipramine in the rat forced swim test by S-HT-4 receptor antagonists. Psychopharmacology (Berl). 1995;119:47-54.
7. Heal DJ, Lister S, Smith SL, Davies CL, Molyneux SG, Green AR. The effects of acute and repeated administration of various antidepressant drugs on clonidineinduced hypoactivity in mice and rats. Newopharmacology. 1983;22:983-992.
8. Racagni G, Brunello N, Mocheti I, Cagiano R, Cuomo V. Presynaptic and transynaptic mechanisms involved in the sub-sensitivity of rat cortical noradrenergic system after long-term antidepressant treatment. Acta Pharmacol Toxicol. 1985;56,190-197.
9. Malinge M, Bourin M, Colombel MC, Larousse G. Additive effects of clonidine and antidepressant drugs in the mouse forced-swimming test. Psychopharmacology (Berl). 1988;96:104-109.
10. Bourin M, Colombel MC, Malinge M, Bradwejn J. Clonidine as a sensitizing agent in the forced swimming test for revealing antidepressant activity. J Psychiatry Neurosci. 1991;16:199-203.
11. Mongeau R, Blier P, de Montigny C. In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of alpha 2-adrenoceptors on 5-hydroxytryptamine terminals in the rat hippocampus. Xaunyn Schmiedebergs Arch Pharmacol. 1993;347:266-272.
12. Bourin M, Hascoet M, Colombel MC, Redrobe JP, Baker GB. Differential effects of clonidine, lithium and quinine in the forced swimming test in mice for antidepressants: possible roles of serotonergic systems. EUT Neuropsychopharmacol. 1996;6:231-236.
13. Redrobe JP, Bourin M. Effects of pretreatment with clonidine, lithium and quinine on the activities of antidepressant drugs in the mouse tail suspension test. Fundam Clin Pharmacol. 1997;ll:381-386.
14. Redrobe JP, Bourin M. Clonidine potentiates the effects of 5-HT]v 5-HTjB and 5-HT2y2c antagonists and 8OH-DPAT in the mouse forced swimming test. Eur Neuropsychopharmacol. 1998,138:198-206.
15. Katz B, Miledi R. Tetrodotoxin-resistant electric activity in presynaptic terminals. / Physiol (Land). 1969;203:459-487.
16. Benoît PR, Mambrini J. Modification of transmitter release by ions which prolong the presynaptic action potential. J Physiol (Land). 1970;210:681-695.
17. + -channel blockers on neurotransmitter release in bullfrog sympathetic ganglia. ; Pharmacol Exp Ther. 1985;235:241-247.
18. Guo WY, Todd KG, Bourin M, Hascoet M. The additive effects of quinine on antidepressant drugs in the forced swimming test in mice. Psychopharmacology (Berl). 1995;121:173-179.
19. Guo WY, Todd KG, Bourin M, Hascoet M, Kouadio F. Additive effects of glyburide and antidepressants in the forced swimming test: evidence for the involvement of potassium channel blockade. Pharmacol Biochem Behav. 1996;54:725-730.
20. Yakel JL, Shao XM, Jackson MB. The selectivity of the channel coupled to the 5-HT3 receptor. Brain Res. 1990;533:46-52.
21. Redrobe JP, Pinot P, Bourin M. The effect of the potassium channel activator, cromakalim, on antidepressant drugs in the forced swimming test in mice. Fundam Clin Pharmacol. 1996;10:524-528.
22. Redrobe JP, MacSweeney CP, Bourin M. The role of 5HTj-4 and 5-HTjg receptors in antidepressant drug actions in the mouse forced swimming test. Eur J Pharmacol. 1996;318:213-220.
23. de Montigny C, Chaput Y, Blier P. Classical and novel targets for antidepressant drugs. Int Acad Biomed Drug Res. 1993;5:8-17.
24. Tome MB, Isaac MT, Harte R, Holland C. Paroxetine and pindolol: a randomised trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Inl Clin Psychopharmacol. 1997;12:81-90.
25. Blier P, Bergeron R. Early onset of therapeutic action in depression and greater efficacy of anlidepressant treatments: are they related? Int Clin Psychopharmacol. 1997;12(suppl 3):S21-S28.
26. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol. 1995;15:217-222.
27. Bourin M, Redrobe JP, Baker GB. Pindolol does not act only on 5-HTj-4 receptors in augmenting antidepressant activity in the -.mouse forced swimming test. Psychopharmacology (Bed). 1998;136:226-234.
28. Artigas F, Romero L, de Montigny C, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HTj -4 antagonists. Trends Keurosci. 1996;19:378-383.
29. Redrobe JP, Bourin M. Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test. Psychopharmacology (Bed). 1998; 138:198-206.
30. Jpffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. / Clin Psychiatry. 1993;54:269-271.
31. Sl.Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry. 1991;52: 217-220.
32. Hoyer D. Functional correlates of serotonin 5-HTj recognition sites. J Recept Res. 1988;8:59-81.
33. Hjorth S. (-)-Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine. Eur J Pharmacol. 1996;303:183-186.
34. Hascoet M, Bourin M, Khimake S. Additive effect of lithium and clonidine with 5-HTj -4 agonists in the forced swimming test. Prog l\europsychopharmacol Biol Psychiatry. 1994;18:381-396.
35. Cervo L, Samanin R. Potential antidepressant properties of 8-hydroxy-2-(di-n-propylamino)tetralin, a selective serotoninn receptor agonist. Eur J Pharmacol. 1987;144:223-229.
36. Giral P, Martin P, Soubrie P, Simon P. Reversal of helpless behavior in rats by putative 5-HT]A agonists. Biol Psychiatry. 1988;23:237-242.
37. Kennet! GA, Dickson SL, Curzon G. Enhancement of some 5-HT-dependent behavioral responses following repeated immobilization in rats. Brain Res. 1985;330:253-263.
38. Kennett GA, Curzon G. Mechanism of action of 8-OHDPAT on a rat model of human depression. In: Bevan P, Cools A, Archer T, Lawrence S, eds. Behavioral Pharmacology of 5-UT. L. Edbaum Associates Publishing; Alahurah, NJ: 1989:225-229.
39. Robinson DS, Alms DR, Shrotriya RC, Messina ME, Wickramaratre P. Serotonergic anxiolytics and treatment of depression. Psychopathology. 1989;22(suppl 1): 22-36.
40. Przegalinski E, Moryl E, Papp M. The effect of 5-HT,A receptor ligands in a chronic mild stress model of depression. Neuropharmaeology. 1995;34:1305-1310.
41. Martin P. l-(2-pyrimidinyl)-piperazine may alter the effects of the 5-HTu agonists in the learned helplessness paradigm in rats. Psychopharmacology (Berl). 1991;104:275-278.
42. Da Rocha MA, Puech AJ, Thiébot Mil. Influence ofanxiolytic drugs on the effects of specific serotonin reuptake inhibitors in the forced swimming test in mice. J Psychopharmacol (Oxf). 1997;11:211-218.
43. Jajoo HK, Mayol RF, Labudcle JA, Blair IA. Melabolism of the anlianxiety drug Luspirone in the rat. Drug Metab Dispos. 1989;17:625-633.
44. Caccia S, Fong MH, Guiso G. Disposition of the psychotropic drugs buspirone, MJ-13805 and piribedil, and of their common active metabolite l-(2-pyrimidinyl)piperazine in the rat. Xenobiolica. 1985;15:835-844.
45. Caccia S, Conti I, Vigano G, Garattini S. l-(2-pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat. Pharmacology. 1986;33:46-51.
46. Cervo L, Grignaschi G, Samanin R. Alpha 2-adrenoreceptor blockade prevents the effect of desipramine in the forced swimming test. Eur J Pharmacol. 1990:175:301-307.
47. Rimele TJ, Henry DE, Lee DKH, Geiger G, Heaslip RJ, Grimes D. Tissue-dependent alpha-adrenoreceptor activity of buspirone and related compounds. ] Pharmacol Exp Ther. 1987;241:771-778.